Stockscreener 앱 받기
45.94
2.81%
-1.33
시간 외 거래:
45.94
전일 마감가:
$47.27
열려 있는:
$47.14
하루 거래량:
438.54K
Relative Volume:
1.15
시가총액:
$935.75M
수익:
$1.77M
순이익/손실:
$-123.74M
주가수익비율:
-5.0098
EPS:
-9.17
순현금흐름:
$-95.21M
1주 성능:
-15.07%
1개월 성능:
-1.75%
6개월 성능:
-47.12%
1년 성능:
-13.19%
1일 변동 폭
$45.30
$47.29
1주일 범위
$45.30
$53.46
52주 변동 폭
$26.70
$91.83
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
명칭
Praxis Precision Medicines Inc
전화
617-300-8460
주소
99 HIGH STREET, 30TH FLOOR, BOSTON
PRAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
45.94 | 1.02B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-03 | 재확인 | H.C. Wainwright | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-08-05 | 개시 | Oppenheimer | Outperform |
| 2024-06-24 | 개시 | Needham | Buy |
| 2024-06-18 | 개시 | Guggenheim | Buy |
| 2024-05-01 | 개시 | Robert W. Baird | Outperform |
| 2023-09-19 | 개시 | Truist | Buy |
| 2022-06-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-12-16 | 개시 | H.C. Wainwright | Buy |
| 2021-08-26 | 개시 | BofA Securities | Buy |
| 2021-04-26 | 개시 | William Blair | Outperform |
| 2020-11-11 | 개시 | Wedbush | Outperform |
| 2020-11-10 | 개시 | Cowen | Outperform |
| 2020-11-10 | 개시 | Evercore ISI | Outperform |
| 2020-11-10 | 개시 | Piper Sandler | Overweight |
모두보기
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
ATTENTION PRAX Shareholders: Lost Money on Praxis Precision Medicines, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Praxis Precision Medicines, Inc. (PRAX) - ACCESS Newswire
Praxis Precision Medicines Q2 results disappoint, stock falls 5.55% - AInvest
Is Praxis Precision Medicines Inc. stock reversal real or fakeSecure Trading Strategy Based on Technical Analysis - Newser
Is Praxis Precision Medicines Inc. meeting your algorithmic filter criteriaReal Market Tracker with Price Action Tools - Newser
Will Praxis Precision Medicines Inc. bounce back from current supportFree Capital Efficiency Optimized Stock Alerts - Newser
Levi & Korsinsky Investigating Whether Praxis Precision Medicines, Inc. (PRAX) Misled InvestorsSecurities Law Violations Possible - ACCESS Newswire
Reversal indicators forming on Praxis Precision Medicines Inc. stockFree Weekly Potential Breakout Stock List - Newser
What is HC Wainwright’s Forecast for PRAX Q3 Earnings? - Defense World
Praxis Precision Medicines’ (PRAX) “Buy” Rating Reiterated at HC Wainwright - Defense World
Praxis Precision Medicines’ Positive Earnings Call Highlights Vormatrigine Success - MSN
Praxis Precision Medicines: Marcio Firm's Insights - AInvest
What is Wedbush’s Forecast for PRAX Q3 Earnings? - Defense World
FY2029 Earnings Forecast for PRAX Issued By HC Wainwright - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc.PRAX - WV News
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Praxis Precision Medicines Grants 3,875 Restricted Stock Units to Strategic New Hires - Stock Titan
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q2 2025 Earnings Call Transcript - Insider Monkey
Praxis Precision Medicines: A Dual-Platform Innovator Capturing the Future of Precision Neurology - AInvest
Praxis Precision Medicines to Participate in Upcoming Fireside C - GuruFocus
Praxis Precision Medicines to Participate in Upcoming Fireside Chat - GlobeNewswire
Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire
Praxis Precision Medicines stock holds Buy rating at Truist on seizure reduction data - Investing.com India
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $33 to $155 - 富途牛牛
Praxis Precision Medicines First Half 2025 Earnings: US$6.60 loss per share (vs US$4.58 loss in 1H 2024) - Yahoo Finance
Praxis’ vormatrigine eliminates seizures in 22% of patients in Phase II trial - Yahoo Finance
Praxis Precision Medicines Inc (PRAX) Q2 2025 Earnings Call Highlights: Vormatrigine Shows ... - Yahoo Finance
Praxis Precision Medicines Inc (PRAX) Q2 2025 Earnings Call Highlights: Vormatrigine Shows ... By GuruFocus - Investing.com Canada
Praxis Precision Medicines Reports Promising Study Results - TipRanks
Decoding Praxis Precision Medicines Inc (PRAX): A Strategic SWOT Insight - GuruFocus
Praxis Precision Medicines to Participate in Virtual Fireside Chat Hosted by Truist Securities - AInvest
Praxis Precision Medicines to Participate in Upcoming Fireside Chat | PRAX Stock News - GuruFocus
Praxis Precision Medicines Shares Surge on Promising Epilepsy Drug Data - MSN
Guggenheim raises Praxis Precision Medicines stock price target on positive seizure drug data - Investing.com Australia
Praxis Precision Medicines stock holds Buy rating at TD Cowen on promising seizure data - Investing.com
Praxis: Positive 8-Week Radiant Study Data Leads To Other Expected Catalysts - Seeking Alpha
Praxis Precision Medicines stock price target raised by Wedbush to $33 - Investing.com
Praxis’ epilepsy drug cut seizure frequency in mid-stage trial - Endpoints News
Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures - Yahoo Finance
Promising Potential of Praxis Precision Medicines: Buy Rating Affirmed by Douglas Tsao - TipRanks
Praxis Precision Medicines, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:PRAX) - Seeking Alpha
A brain biotech slumps even with ‘best case’ seizure data - BioPharma Dive
Quitter jitters? Dropouts mar Praxis FOS vormatrigine phase II - BioWorld MedTech
Praxis Precision Medicines Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Praxis (PRAX) Q2 Loss Widens 90% - The Motley Fool
Praxis Announces Positive Results from RADIANT Study - TipRanks
Praxis Precision Q3 2025 slides: RADIANT study reveals promising epilepsy results - Investing.com Nigeria
Praxis Precision Medicines and the Breakthrough Potential of Vormatrigine in Focal Epilepsy - AInvest
Praxis Precision Medicines, Inc. SEC 10-Q Report - TradingView
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewswire
Praxis Precision stock jumps on trial data (PRAX:NASDAQ) - Seeking Alpha
Praxis Precision Medicines Inc (PRAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):